Drug-induced long QT syndrome

Pharmacological Reviews

Volumn 62, Issue 4, 2010, Pages 760-781

  Kannankeril, Prince ^a   Roden, Dan M ^a   Darbar, Dawood ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ARSENIC TRIOXIDE; ASTEMIZOLE; BEPRIDIL; CHLOROQUINE; CHLORPROMAZINE; CISAPRIDE; CLARITHROMYCIN; DISOPYRAMIDE; DOFETILIDE; DOMPERIDONE; DROPERIDOL; ERYTHROMYCIN; HALOFANTRINE; HALOPERIDOL; IBUTILIDE; ION CHANNEL; LEVACETYLMETHADOL; LIDOFLAZINE; MESORIDAZINE; METHADONE; PENTAMIDINE; PIMOZIDE; PROCAINAMIDE; QUINIDINE; SOTALOL; SPARFLOXACIN; TERFENADINE; THIORIDAZINE; UNINDEXED DRUG;

BRADYCARDIA; CARDIOVASCULAR RISK; CONGENITAL HEART DISEASE; DRUG ACTIVITY; DRUG INDUCED DISEASE; DRUG INFUSION; DRUG MECHANISM; GENE MUTATION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOMICS; HEART ATRIUM FIBRILLATION; HEART PROARRHYTHMIA; HEART REPOLARIZATION; HEART VENTRICLE FIBRILLATION; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; INFUSION RATE; ISOLATED HEART; LONG QT SYNDROME; MALARIA; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; PURKINJE FIBER; QT DISPERSION; REVIEW; RISK ASSESSMENT; SCARLET FEVER; SEX DIFFERENCE; SIDE EFFECT; SUDDEN DEATH; SYNCOPE; TISSUE PREPARATION; TORSADE DES POINTES; TRIANGULATION; TYPHOID FEVER;

ANIMALS; DELAYED RECTIFIER POTASSIUM CHANNELS; HUMANS; LONG QT SYNDROME; PHARMACEUTICAL PREPARATIONS; RISK FACTORS; TORSADES DE POINTES;

EID: 78650122732     PISSN: 00316997     EISSN: 15210081     Source Type: Journal    
DOI: 10.1124/pr.110.003723     Document Type: Review

References (224)

1. Abbott GW, Sesti F, Splawski I, Buck ME, Lehmann MH, Timothy KW, Keating MT, and Goldstein SA (1999) MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 97:175-187.
2. Abrahamsson C, Palmer M, Ljung B, Duker G, Bäärnhielm C, Carlsson L, and Danielsson B (1994) Induction of rhythm abnormalities in the fetal rat heart. A tentative mechanism for the embryotoxic effect of the class III antiarrhythmic agent almokalant. Cardiovasc Res 28:337-344.
3. Aiba T, Shimizu W, Inagaki M, Noda T, Miyoshi S, Ding WG, Zankov DP, Toyoda F, Matsuura H, Horie M, et al. (2005) Cellular and ionic mechanism for drug-induced long QT syndrome and effectiveness of verapamil. J Am Coll Cardiol 45:300-307.
4. Albert CM, Nam EG, Rimm EB, Jin HW, Hajjar RJ, Hunter DJ, MacRae CA, and Ellinor PT (2008) Cardiac sodium channel gene variants and sudden cardiac death in women. Circulation 117:16-23. (Pubitemid 350301143)
5. Altin T, Ozcan O, Turhan S, Ongun Ozdemir A, Akyurek O, Karaoguz R, and Guldal M (2007) Torsade de pointes associated with moxifloxacin: a rare but potentially fatal adverse event. Can J Cardiol 23:907-908. (Pubitemid 350011275)
6. Anderson CL, Delisle BP, Anson BD, Kilby JA, Will ML, Tester DJ, Gong Q, Zhou Z, Ackerman MJ, and January CT (2006) Most LQT2 mutations reduce Kv11.1 (hERG) current by a class 2 (trafficking-deficient) mechanism. Circulation 113: 365-373.
7. Anderson JL and Prystowsky EN (1999) Sotalol: An important new antiarrhythmic. Am Heart J 137:388-409.
8. Antzelevitch C (2008) Drug-induced spatial dispersion of repolarization. Cardiol J 15:100-121.
9. Antzelevitch C and Fish J (2001) Electrical heterogeneity within the ventricular wall. Basic Res Cardiol 96:517-527.
10. Antzelevitch C and Sicouri S (1994) Clinical relevance of cardiac arrhythmias generated by afterdepolarizations. Role of M cells in the generation of U waves, triggered activity and torsade de pointes. J Am Coll Cardiol 23:259-277.
11. Antzelevitch C, Sicouri S, Litovsky SH, Lukas A, Krishnan SC, Di Diego JM, Gintant GA, and Liu DW (1991) Heterogeneity within the ventricular wall. Electrophysiology and pharmacology of epicardial, endocardial, and M cells. Circ Res 69:1427-1449.
12. Appleby M, Mbewu A, and Clarke B (1995) Fluoxetine and ventricular torsade-is there a link? Int J Cardiol 49:178-180.
13. Arking DE, Pfeufer A, Post W, Kao WH, Newton-Cheh C, Ikeda M, West K, Kashuk C, Akyol M, Perz S, et al. (2006) A common genetic variant in the NOS1 regulator NOS1AP modulates cardiac repolarization. Nat Genet 38:644-651.
14. Arya A (2005) Gender-related differences in ventricular repolarization: beyond gonadal steroids. J Cardiovasc Electrophysiol 16:525-527.
15. Bazett HC (1920) An analysis of the time relations of electrocardiograms. Heart 7:353.
16. Becker ML, Visser LE, Newton-Cheh C, Hofman A, Uitterlinden AG, Witteman JC, and Stricker BH (2009) A common NOS1AP genetic polymorphism is associated with increased cardiovascular mortality in users of dihydropyridine calcium channel blockers. Br J Clin Pharmacol 67:61-67.
17. Bloomfield DM, Kost JT, Ghosh K, Hreniuk D, Hickey LA, Guitierrez MJ, Gottesdiener K, and Wagner JA (2008) The effect of moxifloxacin on QTc and implications for the design of thorough QT studies. Clin Pharmacol Ther 84:475-480.
18. Bowlby MR, Peri R, Zhang H, and Dunlop J (2008) hERG (KCNH2 or Kv11.1) K+ channels: screening for cardiac arrhythmia risk. Curr Drug Metab 9:965-970.
19. Brodie BB, Baer JE, and Craig LC (1951) Metabolic products of the cinchona alkaloids in human urine. J Biol Chem 188:567-581.
20. Brodie BB and Udenfriend S (1943) Estimation of quinidine in human plasma, with note of estimation of quinidine. J Pharmacol Exp Ther 78:154.
21. Buff DD, Brenner R, Kirtane SS, and Gilboa R (1991) Dysrhythmia associated with fluoxetine treatment in an elderly patient with cardiac disease. J Clin Psychiatry 52:174-176.
22. Burashnikov A and Antzelevitch C (1998) Acceleration-induced action potential prolongation and early afterdepolarizations. J Cardiovasc Electrophysiol 9:934-948.
23. Burkhart GA, Sevka MJ, Temple R, and Honig PK (1997) Temporal decline in filling prescriptions for terfenadine closely in time with those for either ketoconazole or erythromycin. Clin Pharmacol Ther 61:93-96. (Pubitemid 27072887)
24. Carlsson L (2008) The anaesthetised methoxamine-sensitised rabbit model of torsades de pointes. Pharmacol Ther 119:160-167.
25. Carlsson L, Abrahamsson C, Andersson B, Duker G, and Schiller-Linhardt G (1993) Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisations. Cardiovasc Res 27:2186-2193.
26. Carlsson L, Almgren O, and Duker G (1990) QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit: etiology and interventions. J Cardiovasc Pharmacol 16:276-285.
27. Cavuto NJ, Woosley RL, and SaleM(1996) Pharmacies and prevention of potentially fatal drug interactions. JAMA 275:1086-1087.
28. Chang KC, Barth AS, Sasano T, Kizana E, Kashiwakura Y, Zhang Y, Foster DB, and Marbán E (2008) CAPON modulates cardiac repolarization via neuronal nitric oxide synthase signaling in the heart. Proc Natl Acad Sci USA 105:4477-4482.
29. Chen L, Marquardt ML, Tester DJ, Sampson KJ, Ackerman MJ, and Kass RS (2007) Mutation of an A-kinase-anchoring protein causes long-QT syndrome. Proc Natl Acad Sci USA 104:20990-20995.
30. Cheng HC and Incardona J (2009) Models of torsades de pointes: effects of FPL64176, DPI201106, dofetilide, and chromanol 293B in isolated rabbit and guinea pig hearts. J Pharmacol Toxicol Methods 60:174-184.
31. Chézalviel-Guilbert F, Weissenburger J, Davy JM, Guhennec C, Poirier JM, and Cheymol G (1995) Proarrhythmic effects of a quinidine analog in dogs with chronic A-V block. Fundam Clin Pharmacol 9:240-247.
32. Chow MJ, Piergies AA, Bowsher DJ, Murphy JJ, Kushner W, Ruo TI, Asada A, Talano JV, and Atkinson AJ Jr (1984) Torsade de pointes induced by Nacetylprocainamide. J Am Coll Cardiol 4:621-624.
33. Choy AM, Darbar D, Dell'Orto S, and Roden DM (1999) Exaggerated QT prolongation after cardioversion of atrial fibrillation. J Am Coll Cardiol 34:396-401.
34. Chugh SS, Reinier K, Singh T, Uy-Evanado A, Socoteanu C, Peters D, Mariani R, Gunson K, and Jui J (2009) Determinants of prolonged QT interval and their contribution to sudden death risk in coronary artery disease: the Oregon Sudden Unexpected Death Study. Circulation 119:663-670.
35. Cordes JS, Sun Z, Lloyd DB, Bradley JA, Opsahl AC, Tengowski MW, Chen X, and Zhou J (2005) Pentamidine reduces hERG expression to prolong the QT interval. Br J Pharmacol 145:15-23.
36. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, and Keating MT (1995) A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 80:795-803.
37. Dale KM, Lertsburapa K, Kluger J, and White CM (2007) Moxifloxacin and torsade de pointes. Ann Pharmacother 41:336-340.
38. Dangman KH and Hoffman BF (1981) In vivo and in vitro antiarrhythmic and arrhythmogenic effects of N-acetyl procainamide. J Pharmacol Exp Ther 217:851-862.
39. Darbar D, Hardin B, Harris P, and Roden DM (2007) A rate-independent method of assessing QT-RR slope following conversion of atrial fibrillation. J Cardiovasc Electrophysiol 18:636-641.
40. Darbar D, Kimbrough J, Jawaid A, McCray R, Ritchie MD, and Roden DM (2008) Persistent atrial fibrillation is associated with reduced risk of torsades de pointes in patients with drug-induced long QT syndrome. J Am Coll Cardiol 51:836-842.
41. Davies AJ, Harindra V, McEwan A, and Ghose RR (1989) Cardiotoxic effect with convulsions in terfenadine overdose. BMJ 298:325.
42. de Bruyne MC, Hoes AW, Kors JA, Hofman A, van Bemmel JH, and Grobbee DE (1999) Prolonged QT interval predicts cardiac and all-cause mortality in the elderly. The Rotterdam Study. Eur Heart J 20:278-284.
43. Dessertenne F (1966) [Ventricular tachycardia with 2 variable opposing foci]. Arch Mal Coeur 59:263-272.
44. Donger C, Denjoy I, Berthet M, Neyroud N, Cruaud C, Bennaceur M, Chivoret G, Schwartz K, Coumel P, and Guicheney P (1997) KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome. Circulation 96:2778-2781.
45. Dorian P (2000) Mechanisms of action of class III agents and their clinical relevance. Europace 1:C6-C9.
46. Dumotier BM, Deurinck M, Yang Y, Traebert M, and Suter W (2008) Relevance of in vitro SCREENIT results for drug-induced QT interval prolongation in vivo: a database review and analysis. Pharmacol Ther 119:152-159.
47. Eap CB, Crettol S, Rougier JS, Schläpfer J, Sintra Grilo L, Déglon JJ, Besson J, Croquette-Krokar M, Carrupt PA, and Abriel H (2007) Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clin Pharmacol Ther 81:719-728.
48. El-Sherif N, Caref EB, Chinushi M, and Restivo M (1999) Mechanism of arrhythmogenicity of the short-long cardiac sequence that precedes ventricular tachyarrhythmias in the long QT syndrome. J Am Coll Cardiol 33:1415-1423.
49. Farkas A, Leprán I, and Papp JG (2002) Proarrhythmic effects of intravenous quinidine, amiodarone, D-sotalol, and almokalant in the anesthetized rabbit model of torsade de pointes. J Cardiovasc Pharmacol 39:287-297.
50. Fenichel RR, Malik M, Antzelevitch C, Sanguinetti M, Roden DM, Priori SG, Ruskin JN, Lipicky RJ, Cantilena LR, and Independent Academic Task Force (2004) Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol 15:475-495.
51. Fernandez D, Ghanta A, Kauffman GW, and Sanguinetti MC (2004) Physicochemical features of the HERG channel drug binding site. J Biol Chem 279:10120-10127.
52. Ficker E, Kuryshev YA, Dennis AT, Obejero-Paz C, Wang L, Hawryluk P, Wible BA, and Brown AM (2004) Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol Pharmacol 66:33-44.
53. Fitzgerald PT and Ackerman MJ (2005) Drug-induced torsades de pointes: the evolving role of pharmacogenetics. Heart Rhythm 2:S30-S37.
54. Frey W (1918) [About atrial fibrillation in humans, and its elimination by quinidine.] Berl Klin Wochnschr 55:417-419.
55. Fridericia LS (1920) [Systolic duration in the electrocardiogram in normal humans and in cardiac patients.] Acta Med Scan 53:469.
56. Furutani M, Trudeau MC, Hagiwara N, Seki A, Gong Q, Zhou Z, Imamura S, Nagashima H, Kasanuki H, Takao A, et al. (1999) Novel mechanism associated with an inherited cardiac arrhythmia: defective protein trafficking by the mutant HERG (G601S) potassium channel. Circulation 99:2290-2294.
57. Giles TD and Modlin RK (1968) Death associated with ventricular arrhythmia and thioridazine hydrochloride. JAMA 205:108-110.
58. Gintant GA (2008) Preclinical Torsades-de-Pointes screens: advantages and limitations of surrogate and direct approaches in evaluating proarrhythmic risk. Pharmacol Ther 119:199-209.
59. Guo J, Massaeli H, Li W, Xu J, Luo T, Shaw J, Kirshenbaum LA, and Zhang S (2007) Identification of IKr and its trafficking disruption induced by probucol in cultured neonatal rat cardiomyocytes. J Pharmacol Exp Ther 321:911-920.
60. Hammond TG and Pollard CE (2005) Use of in vitro methods to predict QT prolongation. Toxicol Appl Pharmacol 207:446-450.
61. Hancox JC, McPate MJ, El Harchi A, and Zhang YH (2008) The hERG potassium channel and hERG screening for drug-induced torsades de pointes. Pharmacol Ther 119:118-132.
62. Haverkamp W, Breithardt G, Camm AJ, Janse MJ, Rosen MR, Antzelevitch C, Escande D, Franz M, Malik M, Moss A, et al. (2000) The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res 47:219-233.
63. Hiraoka M, Sawada K, and Kawano S (1986) Effects of quinidine on plateau currents of guinea-pig ventricular myocytes. J Mol Cell Cardiol 18:1097-1106.
64. Hohnloser SH, van de Loo A, and Baedeker F (1995) Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine. J Am Coll Cardiol 26:852-858.
65. Hollister LE and Kosek JC (1965) Sudden death during treatment with phenothiazine derivatives. JAMA 192:1035-1038.
66. Hondeghem LM (1994) Computer aided development of antiarrhythmic agents with class IIIa properties. J Cardiovasc Electrophysiol 5:711-721.
67. Hondeghem LM (2006) Thorough QT/QTc not so thorough: removes torsadogenic predictors from the T-wave, incriminates safe drugs, and misses profibrillatory drugs. J Cardiovasc Electrophysiol 17:337-340.
68. Hondeghem LM, Carlsson L, and Duker G (2001) Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation 103:2004-2013.
69. Hondeghem LM and Hoffmann P (2003) Blinded test in isolated female rabbit heart reliably identifies action potential duration prolongation and proarrhythmic drugs: importance of triangulation, reverse use dependence, and instability. J Cardiovasc Pharmacol 41:14-24.
70. Honig PK, Woosley RL, Zamani K, Conner DP, and Cantilena LR Jr (1992) Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 52: 231-238.
71. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, and Cantilena LR (1993) Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA 269:1513-1518.
72. Hreiche R, Morissette P, and Turgeon J (2008) Drug-induced long QT syndrome in women: review of current evidence and remaining gaps. Gend Med 5:124-135.
73. Imaizumi Y and Giles WR (1987) Quinidine-induced inhibition of transient outward current in cardiac muscle. Am J Physiol 253:H704-H708.
74. January CT and Riddle JM (1989) Early afterdepolarizations: mechanism of induction and block. A role for L-type Ca2+ current. Circ Res 64:977-990.
75. Jenzer HR and Hagemeijer F (1976) Quinidine syncope: torsade de pointes with low quinidine plasma concentrations. Eur J Cardiol 4:447-451.
76. Jervell A and Lange-Nielsen F (1957) Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval and sudden death. Am Heart J 54:59-68.
77. Johnson EA and McKinnon MG (1957) The differential effect of quinidine and pyrilamine on the myocardial action potential at various rates of stimulation. J Pharmacol Exp Ther 120:460-468.
78. Jost N, Virág L, Bitay M, Takács J, Lengyel C, Biliczki P, Nagy Z, Bogáts G, Lathrop DA, Papp JG, et al. (2005) Restricting excessive cardiac action potential and QT prolongation: a vital role for IKs in human ventricular muscle. Circulation 112: 1392-1399.
79. Kääb S, Ritchie MD, Crawford DC, Sinner M, Kannankeril P, Wilde A, Bezzina C, Schulze-Bahr E, Guicheney P, Bishopric N, et al. (2009) Genome-wide association study identifies novel genomic regions associated with drug-induced long QT syndrome (Abstract). Circulation 120:S580.
80. Kääb S, Sinner M, George A, Wilde AJ, Bezzina C, Schulze-Bahr E, Guicheney P, Bishopric N, Myerburg R, Schott JJ, et al. (2008) High-density tag SNP candidate gene analysis identifies IKs as a major modulator of genetic susceptibility to drug induced long QT syndrome (Abstract). Circulation 118:S884.
81. Kannankeril PJ, Roden DM, Norris KJ, Whalen SP, George AL Jr, and Murray KT (2005) Genetic susceptibility to acquired long QT syndrome: pharmacologic challenge in first-degree relatives. Heart Rhythm 2:134-140.
82. Kao WH, Arking DE, Post W, Rea TD, Sotoodehnia N, Prineas RJ, Bishe B, Doan BQ, Boerwinkle E, Psaty BM, et al. (2009) Genetic variations in nitric oxide synthase 1 adaptor protein are associated with sudden cardiac death in US white community - based populations. Circulation 119:940-951.
83. Karjalainen J, Viitasalo M, Mänttäri M, and Manninen V (1994) Relation between QT intervals and heart rates from 40 to 120 beats/min in rest electrocardiograms of men and a simple method to adjust QT interval values. J Am Coll Cardiol 23:1547-1553.
84. Kay GN, Plumb VJ, Arciniegas JG, Henthorn RW, and Waldo AL (1983) Torsade de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients. J Am Coll Cardiol 2:806-817.
85. Kirchhof P, Franz MR, Bardai A, and Wilde AM (2009) Giant T-U waves precede torsades de pointes in long QT syndrome: a systematic electrocardiographic analysis in patients with acquired and congenital QT prolongation. J Am Coll Cardiol 54:143-149.
86. Krantz MJ, Lewkowiez L, Hays H, Woodroffe MA, Robertson AD, and Mehler PS (2002) Torsade de pointes associated with very-high-dose methadone. Ann Intern Med 137:501-504.
87. Kühlkamp V, Mewis C, Bosch R, and Seipel L (2003) Delayed sodium channel inactivation mimics long QT syndrome 3. J Cardiovasc Pharmacol 42:113-117.
88. Kurita T, Ohe T, Marui N, Aihara N, Takaki H, Kamakura S, Matsuhisa M, and Shimomura K (1992) Bradycardia-induced abnormal QT prolongation in patients with complete atrioventricular block with torsades de pointes. Am J Cardiol 69:628-633.
89. Kuryshev YA, Ficker E, Wang L, Hawryluk P, Dennis AT, Wible BA, Brown AM, Kang J, Chen XL, Sawamura K, et al. (2005) Pentamidine-induced long QT syndrome and block of hERG trafficking. J Pharmacol Exp Ther 312:316-323.
90. Kuryshev YA, Wang L, Wible BA, Wan X, and Ficker E (2006) Antimony-based antileishmanial compounds prolong the cardiac action potential by an increase in cardiac calcium currents. Mol Pharmacol 69:1216-1225.
91. Lawrence CL, Bridgland-Taylor MH, Pollard CE, Hammond TG, and Valentin JP (2006) A rabbit Langendorff heart proarrhythmia model: predictive value for clinical identification of torsades de pointes. Br J Pharmacol 149:845-860.
92. Lazzara R (1989) Amiodarone and torsade de pointes. Ann Intern Med 111:549-551.
93. Lazzara R (1993) Antiarrhythmic drugs and torsade de pointes. Eur Heart J 14 (Suppl. H):88-92.
94. Lengyel C, Varró A, Tábori K, Papp JG, and Baczkó I (2007) Combined pharmacological block of I(Kr) and I(Ks) increases short-term QT interval variability and provokes torsades de pointes. Br J Pharmacol 151:941-951.
95. Levy RL (1922) Clinical studies of quinidine. IV. The clinical toxicology of quinidine. J Am Med Assoc 79:1108-1113.
96. Lherm T, Lottin F, Larbi D, Bray M, Legall C, and Caen D (2000) [Torsade de pointes after poisoning with fluoxetine alone]. Presse Med 29:306-307.
97. Liu DW and Antzelevitch C (1995) Characteristics of the delayed rectifier current (IKr and IKs) in canine ventricular epicardial, midmyocardial, and endocardial myocytes. A weaker IKs contributes to the longer action potential of the M cell. Circ Res 76:351-365.
98. Liu K, Yang T, Viswanathan PC, and Roden DM (2005a) New mechanism contributing to drug-induced arrhythmia: rescue of a misprocessed LQT3 mutant. Circulation 112:3239-3246.
99. Liu T, Choi BR, Drici MD, and Salama G (2005b) Sex modulates the arrhythmogenic substrate in prepubertal rabbit hearts with Long QT 2. J Cardiovasc Electrophysiol 16:516-524.
100. Liu XK, Katchman A, Drici MD, Ebert SN, Ducic I, Morad M, and Woosley RL (1998) Gender difference in the cycle length-dependent QT and potassium currents in rabbits. J Pharmacol Exp Ther 285:672-679.
101. Llerena A, Berecz R, de la Rubia A, Norberto MJ, and Benítez J (2000) Use of the mesoridazine/thioridazine ratio as a marker for CYP2D6 enzyme activity. Ther Drug Monit 22:397-401.
102. Luo S, Michler K, Johnston P, and Macfarlane PW (2004) A comparison of commonly used QT correction formulae: the effect of heart rate on the QTc of normal ECGs. J Electrocardiol 37:81-90.
103. Makkar RR, Fromm BS, Steinman RT, Meissner MD, and Lehmann MH (1993) Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 270:2590-2597.
104. Malik M, Färbom P, Batchvarov V, Hnatkova K, and Camm AJ (2002) Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval. Heart 87:220-228.
105. Malik M, Hnatkova K, Ford J, and Madge D (2008) Near-thorough QT study as part of a first-in-man study. J Clin Pharmacol 48:1146-1157.
106. Mank-Seymour AR, Richmond JL, Wood LS, Reynolds JM, Fan YT, Warnes GR, Milos PM, and Thompson JF (2006) Association of torsades de pointes with novel and known single nucleotide polymorphisms in long QT syndrome genes. Am Heart J 152:1116-1122.
107. Medeiros-Domingo A, Kaku T, Tester DJ, Iturralde-Torres P, Itty A, Ye B, Valdivia C, Ueda K, Canizales-Quinteros S, Tusié-Luna MT, et al. (2007) SCN4B-encoded sodium channel beta4 subunit in congenital long-QT syndrome. Circulation 116: 134-142.
108. Milan DJ, Kim AM, Winterfield JR, Jones IL, Pfeufer A, Sanna S, Arking DE, Amsterdam AH, Sabeh KM, Mably JD, et al. (2009) Drug-sensitized zebrafish screen identifies multiple genes, including GINS3, as regulators of myocardial repolarization. Circulation 120:553-559.
109. Milberg P, Reinsch N, Osada N, Wasmer K, Mönnig G, Stypmann J, Breithardt G, Haverkamp W, and Eckardt L (2005) Verapamil prevents torsade de pointes by reduction of transmural dispersion of repolarization and suppression of early afterdepolarizations in an intact heart model of LQT3. Basic Res Cardiol 100:365-371.
110. Mitcheson JS, Chen J, Lin M, Culberson C, and Sanguinetti MC (2000) A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci USA 97:12329-12333.
111. Mohler PJ, Le Scouarnec S, Denjoy I, Lowe JS, Guicheney P, Caron L, Driskell IM, Schott JJ, Norris K, Leenhardt A, et al. (2007) Defining the cellular phenotype of "ankyrin-B syndrome" variants: human ANK2 variants associated with clinical phenotypes display a spectrum of activities in cardiomyocytes. Circulation 115: 432-441.
112. Mohler PJ, Schott JJ, Gramolini AO, Dilly KW, Guatimosim S, duBell WH, Song LS, Haurogné K, Kyndt F, Ali ME, et al. (2003) Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature 421:634-639.
113. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, and Cantilena LR Jr (1990) Torsades de pointes occurring in association with terfenadine use. JAMA 264:2788-2790.
114. Motté G, Coumel P, Abitbol G, Dessertenne F, and Slama R (1970) [The long QT syndrome and syncope caused by spike torsades]. Arch Mal Coeur Vaiss 63:831-853.
115. Napolitano C, Schwartz PJ, Brown AM, Ronchetti E, Bianchi L, Pinnavaia A, Acquaro G, and Priori SG (2000) Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. J Cardiovasc Electrophysiol 11:691-696.
116. Nattel S (2001) Effects of ionic remodeling on cardiac antiarrhythmic drug actions. J Cardiovasc Pharmacol 38:809-811.
117. Nattel S, Duker G, and Carlsson L (2008) Model systems for the discovery and development of antiarrhythmic drugs. Prog Biophys Mol Biol 98:328-339.
118. Newton-Cheh C, Johnson T, Gateva V, Tobin MD, Bochud M, Coin L, Najjar SS, Zhao JH, Heath SC, Eyheramendy S, et al. (2009) Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet 41:666-676.
119. Nishio Y, Makiyama T, Itoh H, Sakaguchi T, Ohno S, Gong YZ, Yamamoto S, Ozawa T, Ding WG, Toyoda F, et al. (2009) D85N, a KCNE1 polymorphism, is a disease-causing gene variant in long QT syndrome. J Am Coll Cardiol 54:812-819.
120. Numaguchi H, Johnson JP Jr, Petersen CI, and Balser JR (2000) A sensitive mechanism for cation modulation of potassium current. Nat Neurosci 3:429-430.
121. Ohno S, Toyoda F, Zankov DP, Yoshida H, Makiyama T, Tsuji K, Honda T, Obayashi K, Ueyama H, Shimizu W, et al. (2009) Novel KCNE3 mutation reduces repolarizing potassium current and associated with long QT syndrome. Hum Mutat 30:557-563.
122. Olshansky B, Martins J, and Hunt S (1982) N-acetyl procainamide causing torsades de pointes. Am J Cardiol 50:1439-1441.
123. Opthof T, Coronel R, Wilms-Schopman FJ, Plotnikov AN, Shlapakova IN, Danilo P Jr, Rosen MR, and Janse MJ (2007) Dispersion of repolarization in canine ventricle and the electrocardiographic T wave: Tp-e interval does not reflect transmural dispersion. Heart Rhythm 4:341-348.
124. Oros A, Beekman JD, and Vos MA (2008) The canine model with chronic, complete atrio-ventricular block. Pharmacol Ther 119:168-178.
125. Panaghie G and Abbott GW (2006) The impact of ancillary subunits on smallmolecule interactions with voltage-gated potassium channels. Curr Pharm Des 12:2285-2302.
126. Paulussen AD, Gilissen RA, Armstrong M, Doevendans PA, Verhasselt P, Smeets HJ, Schulze-Bahr E, Haverkamp W, Breithardt G, Cohen N, et al. (2004) Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J Mol Med 82:182-188.
127. Pfeufer A, Sanna S, Arking DE, Müller M, Gateva V, Fuchsberger C, Ehret GB, Orrú M, Pattaro C, Köttgen A, et al. (2009) Common variants at ten loci modulate the QT interval duration in the QTSCD Study. Nat Genet 41:407-414.
128. Piquette RK (1999) Torsade de pointes induced by cisapride/clarithromycin interaction. Ann Pharmacother 33:22-26.
129. Plaster NM, Tawil R, Tristani-Firouzi M, Canún S, Bendahhou S, Tsunoda A, Donaldson MR, Iannaccone ST, Brunt E, Barohn R, et al. (2001) Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome. Cell 105:511-519.
130. Pollard CE, Valentin JP, and Hammond TG (2008) Strategies to reduce the risk of drug-induced QT interval prolongation: a pharmaceutical company perspective. Br J Pharmacol 154:1538-1543.
131. Pratt CM, Ruberg S, Morganroth J, McNutt B, Woodward J, Harris S, Ruskin J, and Moye L (1996) Dose-response relation between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram: distinguishing a drug effect from spontaneous variability. Am Heart J 131:472-480.
132. Priori SG, Napolitano C, and Schwartz PJ (1999) Low penetrance in the long-QT syndrome: clinical impact. Circulation 99:529-533.
133. Rajamani S, Anderson CL, Anson BD, and January CT (2002) Pharmacological rescue of human K+ channel long-QT2 mutations: human ether-a-go-go-related gene rescue without block. Circulation 105:2830-2835.
134. Rajamani S, Eckhardt LL, Valdivia CR, Klemens CA, Gillman BM, Anderson CL, Holzem KM, Delisle BP, Anson BD, Makielski JC, et al. (2006) Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. Br J Pharmacol 149:481-489.
135. Rautaharju PM, Zhou SH, Wong S, Calhoun HP, Berenson GS, Prineas R, and Davignon A (1992) Sex differences in the evolution of the electrocardiographic QT interval with age. Can J Cardiol 8:690-695.
136. Reant P, Lafitte S, Jaïs P, Serri K, Weerasooriya R, Hocini M, Pillois X, Clementy J, Haïssaguerre M, and Roudaut R (2005) Reverse remodeling of the left cardiac chambers after catheter ablation after 1 year in a series of patients with isolated atrial fibrillation. Circulation 112:2896-2903.
137. Reiffel JA and Appel G (2001) Importance of QT interval determination and renal function assessment during antiarrhythmic drug therapy. J Cardiovasc Pharmacol Ther 6:111-119.
138. Roden DM (1989) Magnesium treatment of ventricular arrhythmias. Am J Cardiol 63:43G-46G.
139. Roden DM (1998) Taking the "idio" out of " idiosyncratic": predicting torsades de pointes. Pacing Clin Electrophysiol 21:1029-1034.
140. Roden DM (2005) An underrecognized challenge in evaluating postmarketing drug safety. Circulation 111:246-248.
141. Roden DM (2008) Repolarization reserve: a moving target. Circulation 118:981-982.
142. Roden DM and Anderson ME (2000) The pause that refreshes, or does it? Mechanisms in torsades de pointes. Heart 84:235-237.
143. Roden DM, Bennett PB, Snyders DJ, Balser JR, and Hondeghem LM (1988) Quinidine delays IK activation in guinea pig ventricular myocytes. Circ Res 62:1055-1058.
144. Roden DM and Hoffman BF (1985) Action potential prolongation and induction of abnormal automaticity by low quinidine concentrations in canine Purkinje fibers. Relationship to potassium and cycle length. Circ Res 56:857-867.
145. Roden DM, Iansmith DH, and Woosley RL (1987) Frequency-dependent interactions of mexiletine and quinidine on depolarization and repolarization in canine Purkinje fibers. J Pharmacol Exp Ther 243:1218-1224.
146. Roden DM and Viswanathan PC (2005) Genetics of acquired long QT syndrome. J Clin Invest 115:2025-2032.
147. Roden DM, Woosley RL, and Primm RK (1986) Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J 111:1088-1093.
148. Roden DM and Yang T (2005) Protecting the heart against arrhythmias: potassium current physiology and repolarization reserve. Circulation 112:1376-1378.
149. Romano C, Gemme G, and Pongiglione R (1963) [Rare cardiac arrhythmias of the pediatric age. II. Syncopal attacks due to paroxysmal ventricular fibrillation. (Presentation of 1st case in Italian pediatric literature)]. Clin Pediatr (Bologna) 45:656-683.
150. Sagie A, Larson MG, Goldberg RJ, Bengtson JR, and Levy D (1992) An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study). Am J Cardiol 70:797-801.
151. Sanguinetti MC, Jiang C, Curran ME, and Keating MT (1995) A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 81:299-307.
152. Sanguinetti MC and Jurkiewicz NK (1990) Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol 96:195-215.
153. Schulze-Bahr E, Wang Q, Wedekind H, Haverkamp W, Chen Q, Sun Y, Rubie C, Hördt M, Towbin JA, Borggrefe M, et al. (1997) KCNE1 mutations cause Jervell and Lange-Nielsen syndrome. Nat Genet 17:267-268.
154. Schwartz PJ and Wolf S (1978) QT interval prolongation as predictor of sudden death in patients with myocardial infarction. Circulation 57:1074-1077.
155. Selzer A and Wray HW (1964) Quinidine syncope. Paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias. Circulation 30: 17-26.
156. Sesti F, Abbott GW, Wei J, Murray KT, Saksena S, Schwartz PJ, Priori SG, Roden DM, George AL Jr, and Goldstein SA (2000) A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci USA 97:10613-10618.
157. Sethuraman V and Sun Q (2009) Impact of baseline ECG collection on the planning, analysis and interpretation of 'thorough' QT trials. Pharm Stat 8:113-124.
158. Shah RR(2005a) Drug-induced QT interval prolongation-regulatory guidance and perspectives on hERG channel studies. Novartis Found Symp 266:251-280; discussion 280-255.
159. Shah RR (2005b) Drugs, QTc interval prolongation and final ICH E14 guideline: an important milestone with challenges ahead. Drug Saf 28:1009-1028.
160. Shah RR and Hondeghem LM (2005) Refining detection of drug-induced proarrhythmia: QT interval and TRIaD. Heart Rhythm 2:758-772.
161. Sherazi S, DiSalle M, Daubert JP, and Shah AH (2008) Moxifloxacin-induced torsades de pointes. Cardiol J 15:71-73.
162. Shimizu W, McMahon B, and Antzelevitch C (1999) Sodium pentobarbital reduces transmural dispersion of repolarization and prevents torsades de Pointes in models of acquired and congenital long QT syndrome. J Cardiovasc Electrophysiol 10:154-164.
163. Shimizu W, Ohe T, Kurita T, Kawade M, Arakaki Y, Aihara N, Kamakura S, Kamiya T, and Shimomura K (1995) Effects of verapamil and propranolol on early after-depolarizations and ventricular arrhythmias induced by epinephrine in congenital long QT syndrome. J Am Coll Cardiol 26:1299-1309.
164. Silva J and Rudy Y (2005) Subunit interaction determines IKs participation in cardiac repolarization and repolarization reserve. Circulation 112:1384-1391.
165. Sipido KR, Volders PG, de Groot SH, Verdonck F, Van de Werf F, Wellens HJ, and Vos MA (2000) Enhanced Ca2+ release and Na/Ca exchange activity in hypertrophied canine ventricular myocytes: potential link between contractile adaptation and arrhythmogenesis. Circulation 102:2137-2144.
166. Snook J, Boothman-Burrell D, Watkins J, and Colin-Jones D (1988) Torsade de pointes ventricular tachycardia associated with astemizole overdose. Br J Clin Pract 42:257-259.
167. Snyders DJ and Chaudhary A (1996) High affinity open channel block by
168. Soyka LF, Wirtz C, and Spangenberg RB (1990) Clinical safety profile of sotalol in patients with arrhythmias. Am J Cardiol 65:74A-81A.
169. Splawski I, Timothy KW, Sharpe LM, Decher N, Kumar P, Bloise R, Napolitano C, Schwartz PJ, Joseph RM, Condouris K, et al. (2004) Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell 119:19-31.
170. Splawski I, Tristani-Firouzi M, Lehmann MH, Sanguinetti MC, and Keating MT (1997) Mutations in the hminK gene cause long QT syndrome and suppress IKs function. Nat Genet 17:338-340.
171. Stadnicka A, Bosnjak ZJ, Kampine JP, and Kwok WM (2000) Modulation of cardiac inward rectifier K+ current by halothane and isoflurane. Anesth Analg 90:824-833.
172. Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK, and VanderLugt JT (1996) Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. Circulation 94:1613-1621.
173. Strasberg B, Kusniec J, Erdman S, Lewin RF, Arditti A, Sclarovsky S, and Agmon J (1986) Polymorphous ventricular tachycardia and atrioventricular block. Pacing Clin Electrophysiol 9:522-526.
174. Strauss HC, Bigger JT Jr, and Hoffman BF (1970) Electrophysiologial and beta-receptor blocking effects of MJ 1999 on dog and rabbit cardiac tissue. Circ Res 26:661-678.
175. Sun ZQ, Thomas GP, and Antzelevitch C (2001) Chromanol 293B inhibits slowly activating delayed rectifier and transient outward currents in canine left ventricular myocytes. J Cardiovasc Electrophysiol 12:472-478.
176. Thomas D, Gut B, Wendt-Nordahl G, and Kiehn J (2002) The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (HERG) potassium channels. J Pharmacol Exp Ther 300:543-548.
177. Thompson D and Oster G (1996) Use of terfenadine and contraindicated drugs. JAMA 275:1339-1341.
178. Thompson KA, Blair IA, Woosley RL, and Roden DM (1987) Comparative in vitro electrophysiology of quinidine, its major metabolites and dihydroquinidine. J Pharmacol Exp Ther 241:84-90.
179. Thompson KA, Murray JJ, Blair IA, Woosley RL, and Roden DM (1988) Plasma concentrations of quinidine, its major metabolites, and dihydroquinidine in patients with torsades de pointes. Clin Pharmacol Ther 43:636-642.
180. Thomsen MB, Beekman JD, Attevelt NJ, Takahara A, Sugiyama A, Chiba K, and Vos MA (2006) No proarrhythmic properties of the antibiotics Moxifloxacin or Azithromycin in anaesthetized dogs with chronic-AV block. Br J Pharmacol 149: 1039-1048.
181. Thomsen MB, Oros A, Schoenmakers M, van Opstal JM, Maas JN, Beekman JD, and Vos MA (2007) Proarrhythmic electrical remodelling is associated with increased beat-to-beat variability of repolarisation. Cardiovasc Res 73:521-530.
182. Topilski I, Rogowski O, Rosso R, Justo D, Copperman Y, Glikson M, Belhassen B, Hochenberg M, and Viskin S (2007) The morphology of the QT interval predicts torsade de pointes during acquired bradyarrhythmias. J Am Coll Cardiol 49:320-328.
183. Torp-Pedersen C, Møller M, Bloch-Thomsen PE, Køber L, Sandøe E, Egstrup K, Agner E, Carlsen J, Videbaek J, Marchant B, et al. (1999) Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 341:857-865.
184. Tsai WC, Tsai LM, and Chen JH (1997) Combined use of astemizole and ketoconazole resulting in torsade de pointes. J Formos Med Assoc 96:144-146.
185. Tzivoni D, Banai S, Schuger C, Benhorin J, Keren A, Gottlieb S, and Stern S (1988) Treatment of torsade de pointes with magnesium sulfate. Circulation 77:392-397.
186. Ueda K, Valdivia C, Medeiros-Domingo A, Tester DJ, Vatta M, Farrugia G, Ackerman MJ, and Makielski JC (2008) Syntrophin mutation associated with long QT syndrome through activation of the nNOS-SCN5A macromolecular complex. Proc Natl Acad Sci USA 105:9355-9360.
187. van Opstal JM, Verduyn SC, Leunissen HD, de Groot SH, Wellens HJ, and Vos MA (2001) Electrophysiological parameters indicative of sudden cardiac death in the dog with chronic complete AV-block. Cardiovasc Res 50:354-361.
188. Vatta M, Ackerman MJ, Ye B, Makielski JC, Ughanze EE, Taylor EW, Tester DJ, Balijepalli RC, Foell JD, Li Z, et al. (2006) Mutant caveolin-3 induces persistent late sodium current and is associated with long-QT syndrome. Circulation 114: 2104-2112.
189. Vincze D, Farkas AS, Rudas L, Makra P, Csík N, Leprán I, Forster T, Csanády M, Papp JG, Varró A, et al. (2008) Relevance of anaesthesia for dofetilide-induced torsades de pointes in alpha1-adrenoceptor- stimulated rabbits. Br J Pharmacol 153:75-89.
190. Viskin S, Zelster D, and Antzelevitch C (2004) When u say "U Waves," what do u mean? Pacing Clin Electrophysiol 27:145-147.
191. Vorperian VR, Zhou Z, Mohammad S, Hoon TJ, Studenik C, and January CT (1996) Torsade de pointes with an antihistamine metabolite: potassium channel blockade with desmethylastemizole. J Am Coll Cardiol 28:1556-1561.
192. Vos MA, de Groot SH, Verduyn SC, van der Zande J, Leunissen HD, Cleutjens JP, van Bilsen M, Daemen MJ, Schreuder JJ, Allessie MA, et al. (1998) Enhanced susceptibility for acquired torsade de pointes arrhythmias in the dog with chronic, complete AV block is related to cardiac hypertrophy and electrical remodeling. Circulation 98:1125-1135.
193. Vos MA, Gorenek B, Verduyn SC, van der Hulst FF, Leunissen JD, Dohmen L, and Wellens HJ (2000) Observations on the onset of torsade de pointes arrhythmias in the acquired long QT syndrome. Cardiovasc Res 48:421-429.
194. Vos MA, Verduyn SC, Gorgels AP, Lipcsei GC, and Wellens HJ (1995) Reproducible induction of early afterdepolarizations and torsade de pointes arrhythmias by d-sotalol and pacing in dogs with chronic atrioventricular block. Circulation 91: 864-872.
195. Voss F, Opthof T, Marker J, Bauer A, Katus HA, and Becker R (2009) There is no transmural heterogeneity in an index of action potential duration in the canine left ventricle. Heart Rhythm 6:1028-1034.
196. Walker AM, Szneke P, Weatherby LB, Dicker LW, Lanza LL, Loughlin JE, Yee CL, and Dreyer NA (1999) The risk of serious cardiac arrhythmias among cisapride users in the United Kingdom and Canada. Am J Med 107:356-362.
197. Wang D, Patel C, Cui C, and Yan GX (2008) Preclinical assessment of drug-induced proarrhythmias: role of the arterially perfused rabbit left ventricular wedge preparation. Pharmacol Ther 119:141-151.
198. Wang Q, Curran ME, Splawski I, Burn TC, Millholland JM, VanRaay TJ, Shen J, Timothy KW, Vincent GM, de Jager T, et al. (1996) Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat Genet 12:17-23.
199. Wang Q, Shen J, Li Z, Timothy K, Vincent GM, Priori SG, Schwartz PJ, and Keating MT (1995a) Cardiac sodium channel mutations in patients with long QT syndrome, an inherited cardiac arrhythmia. Hum Mol Genet 4:1603-1607.
200. Wang Q, Shen J, Splawski I, Atkinson D, Li Z, Robinson JL, Moss AJ, Towbin JA, and Keating MT (1995b) SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell 80:805-811.
201. Wang S, Morales MJ, Liu S, Strauss HC, and Rasmusson RL (1997) Modulation of HERG affinity for E-4031 by [K+]o and C-type inactivation. FEBS Lett 417:43-47.
202. Ward OC (1964) A new familial cardiac syndrome in children. J Ir Med Assoc 54:103-106.
203. Wattigney WA, Mensah GA, and Croft JB (2002) Increased atrial fibrillation mortality: United States, 1980-1998. Am J Epidemiol 155:819-826.
204. Weissenburger J, Nesterenko VV, and Antzelevitch C (2000) Transmural heterogeneity of ventricular repolarization under baseline and long QT conditions in the canine heart in vivo: torsades de pointes develops with halothane but not pentobarbital anesthesia. J Cardiovasc Electrophysiol 11:290-304.
205. Wenckebach KF (1923) Cinchona derivatives in the treatment of heart disorders. JAMA 81:472-474.
206. Wilke RA, Lin DW, Roden DM, Watkins PB, Flockhart D, Zineh I, Giacomini KM, and Krauss RM (2007) Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov 6:904-916.
207. Woosley RL (2000) Drug labeling revisions-guaranteed to fail? JAMA 284:3047-3049.
208. Woosley RL, Chen Y, Freiman JP, and Gillis RA (1993) Mechanism of the cardiotoxic actions of terfenadine. JAMA 269:1532-1536.
209. Wu L, Shryock JC, Song Y, and Belardinelli L (2006) An increase in late sodium current potentiates the proarrhythmic activities of low-risk QT-prolonging drugs in female rabbit hearts. J Pharmacol Exp Ther 316:718-726.
210. Wu Y, Roden DM, and Anderson ME (1999) Calmodulin kinase inhibition prevents development of the arrhythmogenic transient inward current. Circ Res 84:906-912.
211. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, et al. (2002) A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347:1825-1833.
212. Xiao L, Xiao J, Luo X, Lin H, Wang Z, and Nattel S (2008) Feedback remodeling of cardiac potassium current expression: a novel potential mechanism for control of repolarization reserve. Circulation 118:983-992.
213. Yan GX and Antzelevitch C (1996) Cellular basis for the electrocardiographic J wave. Circulation 93:372-379.
214. Yan GX, Rials SJ, Wu Y, Liu T, Xu X, Marinchak RA, and Kowey PR (2001) Ventricular hypertrophy amplifies transmural repolarization dispersion and induces early afterdepolarization. Am J Physiol Heart Circ Physiol 281:H1968-H1975.
215. Yan GX, Shimizu W, and Antzelevitch C (1998) Characteristics and distribution ofM cells in arterially perfused canine left ventricular wedge preparations. Circulation 98:1921-1927.
216. Yang P, Kanki H, Drolet B, Yang T, Wei J, Viswanathan PC, Hohnloser SH, Shimizu W, Schwartz PJ, Stanton M, et al. (2002) Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation 105:1943-1948.
217. Yang T and Roden DM (1996) Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence. Circulation 93:407-411.
218. Yang T, Snyders D, and Roden DM (2001) Drug block of I(kr): model systems and relevance to human arrhythmias. J Cardiovasc Pharmacol 38:737-744.
219. Yang T, Snyders DJ, and Roden DM (1997) Rapid inactivation determines the rectification and [K+]o dependence of the rapid component of the delayed rectifier K+ current in cardiac cells. Circ Res 80:782-789.
220. Yang Y, Yang Y, Liang B, Liu J, Li J, Grunnet M, Olesen SP, Rasmussen HB, Ellinor PT, Gao L, et al. (2010) Identification of a Kir3.4 mutation in congenital long QT syndrome. Am J Hum Genet 86:872-880.
221. Zareba W, Moss AJ, Locati EH, Lehmann MH, Peterson DR, Hall WJ, Schwartz PJ, Vincent GM, Priori SG, Benhorin J, et al. (2003) Modulating effects of age and gender on the clinical course of long QT syndrome by genotype. J Am Coll Cardiol 42:103-109.
222. Zhang S, Zhou Z, Gong Q, Makielski JC, and January CT (1999) Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. Circ Res 84:989-998.
223. Zhou Z, Vorperian VR, Gong Q, Zhang S, and January CT (1999) Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole. J Cardiovasc Electrophysiol 10:836-843.
224. Zygmunt AC, Eddlestone GT, Thomas GP, Nesterenko VV, and Antzelevitch C (2001) Larger late sodium conductance in M cells contributes to electrical heterogeneity in canine ventricle. Am J Physiol Heart Circ Physiol 281:H689-H697.